Drug
Dupilumab Prefilled Syringe
Dupilumab Prefilled Syringe is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
2(50%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
1
25%
Ph phase_2
1
25%
Ph phase_4
2
50%
Phase Distribution
0
Early Stage
1
Mid Stage
3
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
2(50.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Completed(1)
Other(1)
Detailed Status
Recruiting2
unknown1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 21 (25.0%)
Phase 31 (25.0%)
Phase 42 (50.0%)
Trials by Status
recruiting250%
unknown125%
completed125%
Recent Activity
2 active trials
Showing 4 of 4
recruitingphase_3
A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
NCT07309614
recruitingphase_4
Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP
NCT05094570
unknownphase_2
A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome
NCT04244006
completedphase_4
The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment
NCT04358224
Clinical Trials (4)
Showing 4 of 4 trials
NCT07309614Phase 3
A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
NCT05094570Phase 4
Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP
NCT04244006Phase 2
A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome
NCT04358224Phase 4
The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4